| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5834300 | Journal of the American Pharmacists Association | 2016 | 4 Pages |
Abstract
Renal dysfunction caused by TDF was fully reversible in 37.5% of patients. Improvement to at least 50% of baseline was seen in 96.4% of patients. Viral suppression was not compromised when patient was switched from TDF to an alternative nucleoside reverse transcriptase inhibitor.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Agnes Cha, Ashley R. Besignano-Long, Nechama Rothberger, Bupendra Shah,